Cover Image
市場調查報告書

異位性皮膚炎 - 日本的醫藥品的預測與市場分析

Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 293258
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
異位性皮膚炎 - 日本的醫藥品的預測與市場分析 Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
出版日期: 2015年11月03日 內容資訊: 英文 143 Pages
簡介

異位性皮膚炎 (AD) 治療藥市場,這10年較無變化,處於飽和狀態,不過,預期今後10年,最初的生技藥品登場,製作新的先例。

本報告提供日本的異位性皮膚炎 (AD) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 症狀

第4章 疾病的管理

  • 診斷、治療概要
  • 日本

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介:領導品牌
    • Protopic (tacrolimus)
    • Elidel
    • Cyclosporine
    • 其他
  • 產品簡介 :仿單標示外
    • Xolair (omalizumab)
    • Actimmune (干擾素γ-1b)

第6章 機會及未滿足需求

  • 概要

第7章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的有前途藥物
    • Dupilumab (SAR231893/REGN668)
    • AN2728
    • 其他

第8章 市場預測

  • 日本
    • 預測
    • 主要的活動
    • 推動因素、障礙

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC302CFR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2014 to 2024 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.

GlobalData values the atopic dermatitis market in Japan at $397.0m in 2014. Growth within that market will stem from the positive uptake of systemic agents and the pipeline therapy dupilumab. In terms of branded products, Protopic dominates the topical calcineurin inhibitor class in Japan with estimated sales of $31.5m in 2014. Since its key competitor Elidel is not available in Japan, Protopic's strong stance in that market remains relatively unchallenged throughout the 10-year forecast.

Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of Atopic Dermatitis
    • 4.1.4. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Protopic (tacrolimus)
    • 5.3.2. Elidel
    • 5.3.3. Cyclosporine (numerous generic names)
    • 5.3.4. Other Therapeutic Drug Classes Used in Atopic Dermatitis
  • 5.4. Product Profiles - Off-Label Therapies
    • 5.4.1. Xolair (omalizumab)
    • 5.4.2. Actimmune (interferon gamma-1b)

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Systemic Drug for Severe Recalcitrant Patients
    • 6.1.2. Tests that Stratify Patients and Allow for a Tailored Treatment Approach
    • 6.1.3. A Drug that Effectively Controls Patients' Pruritus
    • 6.1.4. Further Research into the Pathophysiology of Atopic Dermatitis
    • 6.1.5. A Drug that Induces Disease Remission
    • 6.1.6. Improved Quality of Life for Both Patients and their Carers

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trials by Therapy Type
  • 7.3. Promising Drugs in Clinical Development
    • 7.3.1. Dupilumab (SAR231893/ REGN668)
    • 7.3.2. AN2728
    • 7.3.3. Other Drugs in Development

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Atopic Dermatitis Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Director of Therapy Analysis and Epidemiology
    • 9.7.5. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Treatment Guidelines for Atopic Dermatitis
  • Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2014
  • Table 4: Country Profile - Japan
  • Table 5: Leading Treatments for Atopic Dermatitis, 2014
  • Table 6: Product Profile - Protopic
  • Table 7: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients
  • Table 8: Protopic SWOT Analysis, 2015
  • Table 9: Global Sales Forecasts ($m) for Protopic, 2014-2024
  • Table 10: Product Profile - Elidel
  • Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies
  • Table 12: Elidel SWOT Analysis, 2015
  • Table 13: Global Sales Forecasts ($m) for Elidel, 2014-2024
  • Table 14: Product Profile - Cyclosporine
  • Table 15: Cyclosporine SWOT Analysis, 2015
  • Table 16: Global Sales Forecasts ($m) for Cyclosporine, 2014-2024
  • Table 17: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2015
  • Table 18: Product Profile - Xolair
  • Table 19: Xolair SWOT Analysis, 2015
  • Table 20: Global Sales Forecasts ($m) Xolair, 2014-2024
  • Table 21: Product Profile - Actimmune
  • Table 22: Actimmune SWOT Analysis, 2015
  • Table 23: Global Sales Forecasts ($m) Actimmune, 2014-2024
  • Table 24: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
  • Table 25: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2015
  • Table 26: Late-Stage Atopic Dermatitis Pipeline, 2015
  • Table 27: Product Profile - Dupilumab
  • Table 28: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of December 2014
  • Table 29: Dupilumab SWOT Analysis, 2015
  • Table 30: Global Sales Forecasts ($m) for Dupilumab, 2014-2024
  • Table 31: Product Profile - AN2728
  • Table 32: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29)
  • Table 33: AN2728 SWOT Analysis, 2015
  • Table 34: Global Sales Forecasts ($m) for AN2728, 2014-2024
  • Table 35: Drugs in Early-stage Clinical Development for Atopic Dermatitis, 2015
  • Table 36: Sales Forecasts ($m) for Atopic Dermatitis in Japan, 2012-2022
  • Table 37: Key Event Impacting Sales for Atopic Dermatitis in Japan, 2014-2024
  • Table 38: Atopic Dermatitis Market in Japan - Drivers and Barriers, 2014-2024
  • Table 39: Key Launch Dates
  • Table 40: Key Patent Expiries
  • Table 41: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
  • Figure 3: Atopic Dermatitis Therapeutics - Clinical Trials by Therapy Type and Development Stage, October 2015
  • Figure 4: Atopic Dermatitis - Phase III Pipeline, December 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2014-2024
  • Figure 6: Sales for Atopic Dermatitis in Japan by Drug Class, 2014-2024
Back to Top